AMGN Stock Price Today (September 2026) — Amgen Inc. Analysis & Key Metrics 2026-09-04
Amgen Inc. (AMGN) is trading at $437.23, down 1.55% today (as of September 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $388.48 (-11.1% upside).
- Volatility remains elevated (21.50% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (9.50% YoY) alongside significant competitive pressures.
AMGN Stock Analysis: Key Metrics & Valuation (September 2026)
Concise, actionable data for investors
Amgen Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $277.10B
P/E Ratio
Forward P/E: 17.62
Revenue Growth
Year over Year
Analyst Target
+-11.1% upside potential
Key Investor Questions About AMGN
What investors need to know before buying
Based on current market data, AMGN presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 60.57)
- Fundamentals say: Caution warranted (high leverage concerns)
AMGN's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for AMGN investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $57.30B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, AMGN stock traded between $269.77 and $447.03—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 21.50% annualized volatility and β=0.51, the stock exhibits low sensitivity to market moves—making AMGN suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
A Novartis Heart Drug Trial Stumbles. Can a Rare-Disease Treatment Lift Shares?
In a consequential week for Novartis, the Swiss drug maker released results for two of three trials that Wall Street has watched for in the second half of the year.
NVS, IONS, AMGN Stocks Drop After-Hours — What’s Driving The Selloff?
Novartis said on Friday that its late-stage trial of pelacarsen failed to reduce the risk of cardiovascular events.
Revolution Medicines Got Its Breakthrough—What Moves It Next?
FDA approved Revolution Medicines' RASONQUE for pancreatic cancer, but RVMD stock stayed flat as investors had priced in the news early, with rising expenses now in focus.
Amgen (AMGN) Says Repatha Reduced Mortality Before a First Heart Attack or Stroke. Can Earlier Use Expand the Market?
Amgen Inc. (NASDAQ:AMGN) reported that Repatha reduced the risk of all-cause mortality by 20% in a prespecified secondary analysis of the Phase 3 VESALIUS-CV trial. The study enrolled more than 12,000 high-risk adults without a previous heart attack or stroke and followed them for a median of 4.6 years. The mortality reduction began to appear […]
AMGN's MariTide: Can Convenience Drive its Obesity Market Share?
Amgen's MariTide could target obesity with less frequent dosing, offering a convenience edge as competition from Lilly and Novo Nordisk intensifies.
1 Healthcare Stock for Long-Term Investors and 2 We Ignore
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 23.2% over the past six months, topping the S&P 500 by 11.5 percentage points.
Why Is Amgen (AMGN) Up 8.6% Since Last Earnings Report?
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is Amgen (AMGN) Reasonable Or Rich As Cash Flow Improves?
Amgen stock has logged a strong 5 year run, yet current valuation checks send mixed signals as the intrinsic value estimate suggests a discount while market based multiples look closer to fair. Over 5 years, Amgen has returned 134.2%, which means anyone looking at the stock today is weighing fresh gains against the chance that the easy part of the move is already behind it. New clinical data around Repatha and Tezspire can support expectations for future cash flows, while ongoing trial and...
TEZSPIRE’s Positive EoE Phase 3 Results Could Be A Game Changer For Amgen (AMGN)
Amgen and AstraZeneca recently reported positive Phase 3 CROSSING results showing TEZSPIRE improved histologic remission and dysphagia symptoms in patients with eosinophilic esophagitis, with effects sustained through week 52 and a safety profile broadly consistent with prior use. Because EoE remains poorly controlled for nearly half of patients on existing therapies, TEZSPIRE’s epithelial-targeting mechanism could meaningfully expand its role beyond severe asthma and nasal polyps if...
Amgen Stock Signals Its Confidence. The Market Agrees.
The real bet is on what lies beyond this year's performance: a pipeline that could change everything.
Explore More Analysis for AMGN
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Frequently Asked Questions
Common investor questions about Amgen Inc.
Amgen Inc. (AMGN) is currently trading at $437.23. The RSI (14-day) is at 60.6, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $388.48 implies 11.1% downside from current levels. Volatility is moderate at 21.5% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Amgen Inc. (AMGN): The trailing P/E ratio is 27.17, which is in line with broader market averages. The forward P/E is 17.62, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 2.29, above 2.0, suggesting the stock may be overvalued relative to its expected growth. Price-to-Book is 20.22. Price-to-Sales is 6.21. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 29 analysts covering AMGN, the consensus price target is $388.48. This represents a 11.1% downside from the current price of $437.23. The range spans from a low target of $230.00 to a high target of $457.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Amgen Inc. (AMGN) pays a dividend with a current yield of approximately 2.31%. The annualized dividend rate is $9.80 per share. The payout ratio is 60.9%, which is moderate and suggests adequate earnings coverage for the dividend. The most recent ex-dividend date was 2026-08-21T00:00:00.000Z.
Key risks for Amgen Inc. (AMGN) investors include: 1. Elevated debt levels (D/E ratio of 490.28) which could pressure margins in a rising rate environment. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Amgen Inc.'s (AMGN) current debt and financial health profile: Total debt stands at $57.30B. The debt-to-equity ratio is 490.28, which is high and could pose financial risk if earnings decline or borrowing costs increase. The current ratio is 1.37, indicating adequate short-term liquidity. The quick ratio is 0.95. The company holds $13.99B in cash and equivalents. Free cash flow is positive at $8.65B, providing a cushion for debt servicing and shareholder returns.